Cancers | Free Full-Text | How to Manage Patients with Lenalidomide-Refractory Multiple Myeloma
Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of the Phase 3 MAIA Study
547-Lenalidomide and dexamethasone oral | eviQ
Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma - ScienceDirect
VisualAbstract: Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma | 2 Minute Medicine
Lenalidomide with Low- or High-Dose Dexamethasone for Patients with Newly Diagnosed Multiple Myeloma (MM) | Research To Practice
547-Lenalidomide and dexamethasone oral | eviQ
Lenalidomide in Combination With Dexamethasone in Newly Diagnosed Multiple Myeloma - The ASCO Post
Primary treatment of light-chain amyloidosis with bortezomib, lenalidomide, and dexamethasone - ScienceDirect
Lenalidomide, Bortezomib, and Dexamethasone Plus ASCT Delays Progression in Myeloma
Recommendations for MM front-line therapy. ASCT = autologous stem cell... | Download Scientific Diagram
Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma - ScienceDirect
Tailored lenalidomide regimen benefits older patients with multiple myeloma
Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma | NEJM
VisualAbstract: Carfilzomib, dexamethasone, and lenalidomide superior to lenalidomide monotherapy for multiple myeloma | 2 Minute Medicine
Lenalidomide, Bortezomib, and Dexamethasone as Induction Therapy Before Autologous Stem Cell Transplant for Multiple Myeloma - NCBI Bookshelf
547-Lenalidomide and dexamethasone oral | eviQ
Lenalidomide versus lenalidomide + dexamethasone prolonged treatment after second‐line lenalidomide + dexamethasone induction in multiple myeloma - Lund - 2018 - Cancer Medicine - Wiley Online Library
Lenalidomide with Low- or High-Dose Dexamethasone for Patients with Newly Diagnosed Multiple Myeloma (MM) | Research To Practice
ECOG E4A03 - Lenalidomide plus low-dose dexamethasone - Multiple Myeloma Clinical Trials
Lenalidomide, Dexamethasone, and Carfilzomib for Newly Diagnosed Multiple Myeloma | Cancer Nursing Today
Cost-effectiveness of lenalidomide in combination with dexamethasone compared to bortezomib in combination with dexamethasone for the second-line treatment of multiple myeloma in Chile - Medwave
Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial -
Carfilzomib/Lenalidomide/Dexamethasone → Lenalidomide Extended Dosing for Newly Diagnosed MM | Research To Practice
Initial results of daratumumab + lenalidomide in frail patients: The IFM 2017-03 trial
Elotuzumab plus lenalidomide and dexamethasone for newly diagnosed multiple myeloma: a randomized, open-label, phase 2 study in Japan | International Journal of Hematology
Bortezomib, lenalidomide, and dexamethasone with panobinostat for front-line treatment of patients with multiple myeloma who are eligible for transplantation: a phase 1 trial - The Lancet Haematology
